Home
/

PCOS and Pregnancy: What You Need to Know

REVIEWED BY
Bill Maish, MD
Clinical Content Consultant
Published
May 30, 2026
Last updated
May 30, 2026
Key takeaway:

PCOS does not cause infertility outright — it makes ovulation irregular or absent, and most women with PCOS can conceive with appropriate support. PCOS accounts for roughly 80% of anovulatory infertility cases, with insulin resistance present in up to 70% of affected women regardless of weight. Tracking insulin, testosterone, and AMH helps reveal which metabolic factors may be limiting fertility.

Read more →
Table of contents

You've been diagnosed with PCOS and now you're wondering what it means for starting a family. The internet is full of worst-case scenarios, but the reality is more nuanced. Most women with PCOS can and do get pregnant, though the path often looks different than expected.

What PCOS Actually Does to Fertility

PCOS doesn't make you infertile. It makes ovulation irregular or absent, which narrows your fertile window. In a typical cycle, follicle-stimulating hormone (FSH) helps an egg mature, luteinizing hormone (LH) triggers its release, and ovulation happens predictably. In PCOS, elevated insulin and androgens disrupt this sequence. The ovaries develop multiple small follicles that don't mature fully, LH stays chronically elevated relative to FSH, and ovulation either doesn't happen or happens unpredictably.

This is why PCOS accounts for roughly 80% of anovulatory infertility cases. But anovulatory doesn't mean never ovulating. Many women with PCOS ovulate sporadically, and even those who don't ovulate spontaneously often respond well to treatment. With appropriate treatment, many women with PCOS can conceive, though it may take longer than the general population average. With ovulation-inducing medications like letrozole or clomiphene, cumulative pregnancy rates over multiple cycles can be substantial, though individual results vary based on age, BMI, and metabolic factors.

The core issue is hormonal, not structural. Your ovaries aren't damaged. They're responding to the wrong signals, primarily from insulin.

How PCOS Affects Hormones, Metabolism, and Pregnancy Risk

Insulin resistance and ovulation

Insulin resistance is present in up to 70% of women with PCOS, regardless of weight. When cells resist insulin's signal to absorb glucose, the pancreas compensates by producing more insulin. Elevated insulin stimulates the ovaries to produce excess androgens like testosterone and disrupts the normal FSH-to-LH ratio needed for ovulation.

High androgens interfere with follicle maturation. Eggs start developing but stall before reaching ovulation. This is why anti-Müllerian hormone (AMH), a marker of ovarian reserve, is often elevated in PCOS. It reflects the accumulation of small, immature follicles rather than true ovarian health.

Pregnancy complications

Once pregnant, women with PCOS face higher rates of gestational diabetes, preeclampsia, preterm birth, and miscarriage. The same insulin resistance that disrupts ovulation increases glucose intolerance during pregnancy. Elevated androgens and chronic low-grade inflammation, common in PCOS, also contribute to placental dysfunction and blood pressure dysregulation.

This doesn't mean complications are inevitable. It means monitoring is essential. Women with PCOS benefit from earlier glucose screening, closer blood pressure tracking, and proactive management of weight gain during pregnancy.

Hormonal shifts during pregnancy

Pregnancy itself temporarily improves some PCOS symptoms. Rising estrogen and progesterone suppress LH and androgen production. Insulin sensitivity may temporarily improve in early pregnancy (approximately weeks 6 to 20), but it progressively declines in the second and third trimesters as placental hormones such as human placental lactogen and progesterone drive physiological insulin resistance to redirect glucose to the fetus. Androgen levels generally decrease during pregnancy as rising estrogen and progesterone suppress LH. PCOS symptoms typically return postpartum as these hormonal shifts improve.

What Drives Fertility Challenges in PCOS

Understanding which metabolic factors are limiting your fertility helps determine the most effective intervention strategy.

Insulin resistance

Insulin resistance is the upstream driver. Even in lean women with PCOS, insulin signaling is often impaired. This triggers a cascade: excess insulin stimulates ovarian androgen production, androgens block normal follicle development, and ovulation becomes irregular or absent. Improving insulin sensitivity, whether through berberine, magnesium, or lifestyle changes, often restores ovulation without additional fertility treatment.

Excess androgens

Elevated testosterone and other androgens interfere with the hormonal signals that mature and release eggs. Androgens also thicken the outer layer of the ovary, making it harder for a mature egg to break through.

Chronic inflammation

Low-grade inflammation, reflected in markers like high-sensitivity C-reactive protein (hs-CRP), is common in PCOS. Inflammation worsens insulin resistance and may impair egg quality. Anti-inflammatory strategies, including omega-3 supplementation and reducing processed food intake, can improve metabolic and reproductive outcomes.

Weight and body composition

Excess body fat, particularly visceral fat, worsens insulin resistance and androgen production. Even a 5 to 10% reduction in body weight can restore ovulation in many women with PCOS. In one study, 60% of anovulatory women who achieved at least 5% weight loss experienced spontaneous ovulation. This isn't about achieving a specific BMI. It's about reducing the metabolic load that's suppressing normal ovarian function.

Why Fertility Outcomes Vary So Much

Degree of insulin resistance

Not all women with PCOS have the same level of insulin resistance. Those with higher fasting insulin or elevated HOMA-IR scores tend to have more difficulty ovulating and may require more aggressive metabolic intervention. Women with normal insulin sensitivity but elevated androgens often respond quickly to ovulation-inducing medications.

Age and ovarian reserve

Younger women with PCOS generally have better fertility outcomes. Egg quality declines with age in all women, but the baseline ovulatory dysfunction in PCOS compounds this effect. AMH levels, while elevated in PCOS, still decline over time.

Prior dieting history and metabolic adaptation

Repeated cycles of restrictive dieting can worsen metabolic flexibility and make weight loss harder. Women with a history of yo-yo dieting may have more difficulty improving insulin sensitivity through lifestyle changes alone. This doesn't mean it's impossible, but it may require a more gradual, sustainable approach rather than aggressive calorie restriction.

Genetic and ethnic differences

PCOS presents differently across populations. Women of South Asian descent tend to have more severe insulin resistance and higher diabetes risk. Women of East Asian descent may have milder metabolic features but more pronounced hyperandrogenism. These differences influence which interventions are most effective.

Turning Metabolic Insight Into a Fertility Strategy

Fertility in PCOS isn't a single-number diagnosis. It's a metabolic picture that includes insulin sensitivity, androgen levels, ovarian reserve, and inflammatory markers. Testing fasting glucose, insulin, hemoglobin A1c, testosterone, and AMH gives you a baseline. Tracking these markers over time shows whether lifestyle changes, supplements, or medications are moving you in the right direction.

Ovulation can be tracked through basal body temperature, ovulation predictor kits, or progesterone testing in the second half of your cycle. If you're ovulating regularly, time is on your side. If you're not, the next step is identifying which metabolic lever to pull: insulin, androgens, inflammation, or weight.

If you're navigating PCOS and pregnancy, Superpower's 100+ biomarker panel can show you exactly where your metabolism, hormones, and inflammation stand, so you're making decisions based on data, not guesswork.

FAQs

Yes. Many women with PCOS conceive naturally, especially if they ovulate sporadically. Lifestyle changes like weight loss, improved diet, and regular exercise can restore ovulation without medication. However, if you're not ovulating regularly after several months of lifestyle modification, fertility treatment may improve your chances.
It varies widely. Women with PCOS who ovulate regularly may conceive within a year, similar to the general population. Those with anovulation may take longer without treatment. With ovulation-inducing medications like letrozole, the PPCOS II trial showed cumulative live birth rates of approximately 28% over five treatment cycles. Cumulative conception rates improve with additional treatment cycles and may approach 50% or higher over time, compared to approximately 85% within a year in the general population.
Yes. Women with PCOS have higher miscarriage rates, likely due to insulin resistance, elevated androgens, and inflammation affecting early placental development. Managing insulin sensitivity and maintaining stable blood sugar during early pregnancy may reduce this risk.
Earlier is generally better. Fertility declines with age in all women, and PCOS adds an additional layer of complexity. Women in their 20s and early 30s have more time to optimize metabolic health and respond to treatment. However, many women with PCOS conceive successfully in their mid-to-late 30s with appropriate management.
Insulin resistance can be significantly improved, though whether it's fully "improved" depends on individual factors. Weight loss, strength training, and dietary changes that reduce refined carbohydrates and increase fiber improve insulin sensitivity in most women. Supplements like inositol and berberine also show benefit. Tracking fasting insulin and HOMA-IR over time shows whether your approach is working.
Not necessarily. Lean women with PCOS can also have fertility challenges, and weight loss isn't always the solution. However, if you're overweight and insulin-resistant, even modest weight loss often restores ovulation. The goal isn't a specific number on the scale but improving metabolic function.

References

  1. Dennett, C. C., & Simon, J. (2015). The role of polycystic ovary syndrome in reproductive and metabolic health: overview and approaches for treatment. Diabetes spectrum : a publication of the American Diabetes Association, 28(2), 116-20. https://doi.org/10.2337/diaspect.28.2.116
  2. Azargoon, A., Alavy Toussy, J., & Fakhr Darbanan, F. (2012). Pregnancies following the use of sequential treatment of metformin and incremental doses of letrozole in clomiphen-resistant women with polycystic ovary syndrome. Iranian journal of reproductive medicine, 10(1), 33-40. https://pubmed.ncbi.nlm.nih.gov/25242972/
  3. Amisi, C. A. (2022). Markers of insulin resistance in Polycystic ovary syndrome women: An update. World journal of diabetes, 13(3), 129-149. https://doi.org/10.4239/wjd.v13.i3.129
  4. Qin, J. Z., Pang, L. H., Li, M. J., Fan, X. J., Huang, R. D., & Chen, H. Y. (2013). Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reproductive biology and endocrinology : RB&E, 11, 56. https://doi.org/10.1186/1477-7827-11-56
  5. Crosignani, P. G., Colombo, M., Vegetti, W., Somigliana, E., Gessati, A., & Ragni, G. (2003). Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Human reproduction (Oxford, England), 18(9), 1928-32. https://doi.org/10.1093/humrep/deg367
  6. Legro, R. S., Brzyski, R. G., Diamond, M. P., Coutifaris, C., Schlaff, W. D., Casson, P., Christman, G. M., Huang, H., Yan, Q., Alvero, R., Haisenleder, D. J., Barnhart, K. T., Bates, G. W., Usadi, R., Lucidi, S., Baker, V., Trussell, J. C., Krawetz, S. A., Snyder, P., ... NICHD Reproductive Medicine Network (2014). Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. The New England journal of medicine, 371(2), 119-29. https://doi.org/10.1056/NEJMoa1313517

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey